drugset / Trial / NCT06366490
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
Timeline
- Start
- 2026-02-12
- Primary completion
- 2026-11
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Innocell | Cell therapy | — | Other |
| Background | 1018 ISS | Unknown | — | Other |